Using melanin as an adjuvant, Altevax has developed an immunotherapy that triggers a strong antigen-specific immune response of CD8+ and CD4+ T cells. Altevax is committed to bringing its innovative anticancer and anti-infectious technology to patients, to treat diseases that have no available cure today.